928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Kim, S-B., Keam, B., Shin, S., Chae, Y.S., Seo, S., Park, K., Kim, T.M., Park, L.C., Hong, S-B., Lim, E., Lee, S., Ahn, M-J.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.1043
Date:
September, 2020
File:
PDF, 116 KB
2020
File converter
More search results
More benefits 
